BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34185393)

  • 1. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.
    Fenu E; O'Neill SS; Insuasti-Beltran G
    Int J Lab Hematol; 2021 Dec; 43(6):1458-1464. PubMed ID: 34185393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
    Al-Achkar W; Moassass F; Youssef N; Wafa A
    J BUON; 2016; 21(2):444-9. PubMed ID: 27273956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
    Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
    Rivera D; Cui W; Gao J; Peker D; Zhang QY; Dewar R; Qiu L; Konoplev S; Hu Z; Sasaki K; Hu AY; E S; Liu M; Fang H; Wang W; Tang G; Apperley JF; Hochhaus A; Cortes JE; Khoury JD; Medeiros LJ; Jabbour E; Hu S
    Mod Pathol; 2024 Feb; 37(2):100406. PubMed ID: 38104892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases.
    Aye le L; Loghavi S; Young KH; Siddiqi I; Yin CC; Routbort MJ; Liang M; Eilerman K; Medeiros LJ; Brynes RK; Bueso-Ramos C
    Ann Diagn Pathol; 2016 Apr; 21():53-8. PubMed ID: 27040932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish.
    Xu M; Ye Y; Ye Z; Xu S; Liu W; Xu J; Zhang Y; Liu Q; Huang Z; Zhang W
    Haematologica; 2020 Mar; 105(3):674-686. PubMed ID: 31289206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
    Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.
    Cortés AA; Olmedillas S; Serrano-López J; Lainez-González D; Castaño T; Iñiguez R; Lopez-Lorenzo JL; García A; Atance M; Sánchez RNS; Lopez CB; Arranz MG; Sillero PL; Alonso-Dominguez JM
    Mol Diagn Ther; 2020 Oct; 24(5):593-600. PubMed ID: 32875515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia.
    Jönsson S; Olsson B; Jacobsson S; Palmqvist L; Ricksten A; Ekeland-Sjöberg K; Wadenvik H
    Scand J Clin Lab Invest; 2011 Feb; 71(1):7-11. PubMed ID: 20863169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
    Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.
    Lichty BD; Keating A; Callum J; Yee K; Croxford R; Corpus G; Nwachukwu B; Kim P; Guo J; Kamel-Reid S
    Br J Haematol; 1998 Dec; 103(3):711-5. PubMed ID: 9858221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
    Ogunleye F; Ibrahim M; Allen E; Brennan N; Huang J; Yu Z; Huben M; Jaiyesimi I
    J Oncol Pract; 2016 Dec; 12(12):e1001-e1005. PubMed ID: 27624943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network.
    Schäfer V; White HE; Gerrard G; Möbius S; Saussele S; Franke GN; Mahon FX; Talmaci R; Colomer D; Soverini S; Machova Polakova K; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):3081-3089. PubMed ID: 33677711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
    Gorbenko AS; Stolyar MA; Vasiliev EV; Mikhalev MA; Bakhtina VI; Olkhovik TI; Mochalova EE; Orlova KE; Olkhovskiy IA
    Klin Lab Diagn; 2021 Sep; 66(9):571-576. PubMed ID: 34543537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
    PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
    van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC
    Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.